NBIX -Long -TP>25%NASDAQ:NBIX
- LONG - RISK 1/5 - TP > 25%
We already have a buy position.
Good luck to everyone...
==============================
21.106 BRL
1.21 B BRL
9.17 B BRL
99.05 M
About Neurocrine Biosciences, Inc.
Sector
CEO
Kyle W. Gano
Headquarters
San Diego
Website
Founded
1992
ISIN
BRN1BIBDR009
FIGI
BBG00XV3YMP3
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
NBIX -Long -TP>25%NASDAQ:NBIX
-Long
-TP>25-30% and more
-waiting for a point to enter a long position
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-o
Textbook bullish flagIt looks like a beautiful flag (or pennant) to me, with high volume at the pole and the volume drying up during the consolidation.
I am expecting continuation.
(Potential Trade) NBIX(13 May 2024)
Disclaimer:
All information posted are the author's own trades/potential trades.
The author is not a certified Financial Advisor and do not have the certifications to provide financial advice.
These information are strictly for educational purposes only and do not constitute any finan
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.
Investor and trader interest seems to be moderately increasing in the past week. The combined
MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket
before 7:45 AM
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges
Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidat
Neurocrine Biosciences (NBIX: NASDAQ)Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030,
NBIX view(personal)For this stock i have done some deep analysis including looking at the financial reports and estimated points provided by big bank analyst. i have come to the conclusion that after this close below the strong daily support. this pair is likely going to go to the 95 dollar zone within 2 weeks and fr
$NBIX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $NBIX after a negative under reaction following its earnings release placing the stock in drift D .
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where N1BI34 is featured.
